$1.915
-0.015[-0.78%]
At close: May 28
$1.88
-0.0350[-1.83%]
After Hours: 9:27AM EDT
Xeris Biopharma Holdings
(NASDAQ:XERS)Latest News for Xeris Biopharma Holdings Stock (NASDAQ:XERS)
Xeris Biopharma Holdings Stock (NASDAQ: XERS)
Categories: All
Monday, May 13, 2024
Friday, May 10, 2024
Thursday, May 09, 2024
Monday, May 06, 2024
- Why Are Xeris Biopharma Shares Moving Monday?Dylan Berman - May 6, 2024, 11:37AM
- Xeris shares are trading higher after the company announced an exclusive worldwide collaboration and license agreement with Beta Bionics.Benzinga Newsdesk - May 6, 2024, 7:07AM
- Xeris Biopharma Enters Into an Exclusive Worldwide Collaboration and License Agreement with Beta Bionics, Financial Terms UndisclosedBenzinga Newsdesk - May 6, 2024, 7:01AM
Thursday, March 28, 2024
- Xeris Biopharma Holdings shares are trading higher after Oppenheimer initiated coverage on the stock with an Outperform rating and announced a price target of $5.Benzinga Newsdesk - Mar 28, 2024, 7:12AM
- Oppenheimer Initiates Coverage On Xeris Biopharma Holdings with Outperform Rating, Announces Price Target of $5Benzinga Newsdesk - Mar 28, 2024, 6:51AM
Thursday, March 07, 2024
Wednesday, March 06, 2024
- Xeris Biopharma Holdings shares are trading lower after the company reported Q4 financial results.Benzinga Newsdesk - Mar 6, 2024, 10:54AM
- Xeris Biopharma Expects 2024 Revenue Of $170M-$200M Versus Consensus Of $184.11M; Year-End Cash, Cash Equivalents, And Short-term Investments Of $55M-$75MBenzinga Newsdesk - Mar 6, 2024, 7:08AM
- Xeris Biopharma Holdings Q4 GAAP EPS $(0.10), Inline, Sales $44.39M Beat $43.55M EstimateBenzinga Newsdesk - Mar 6, 2024, 7:04AM
- Xeris Refinances Its $150M Senior Secured Term Loan Facility With Hayfin CapitalBenzinga Newsdesk - Mar 6, 2024, 7:01AM
- Earnings Scheduled For March 6, 2024Benzinga Insights - Mar 6, 2024, 5:00AM
Tuesday, March 05, 2024
Wednesday, January 10, 2024
- Why WD-40 Shares Are Trading Higher By Over 17%? Here Are Other Stocks Moving In Wednesday's Mid-Day SessionAvi Kapoor - Jan 10, 2024, 1:06PM
- Xeris Biopharma Enters Into An Exclusive Worldwide License Agreement With Amgen For Xeriject Formulation Of Teprotumumab For Thyroid Eye Disease; Xeris Has The Potential To Receive $75M In Development And Regulatory MilestonesBenzinga Newsdesk - Jan 10, 2024, 8:02AM
Thursday, January 04, 2024
- Xeris Biopharma shares are trading higher after the company updated its outlook for full year 2023.Benzinga Newsdesk - Jan 4, 2024, 10:59AM
- Lamb Weston Posts Upbeat Results, Joins Omega Therapeutics, Allstate And Other Big Stocks Moving Higher On ThursdayAvi Kapoor - Jan 4, 2024, 10:12AM
- Xeris Biopharma Sees FY23 Revenue At High End Of Previous Guidance Of $160M-$165M Vs. Estimate Of $161.96M; Expects To Be Cash Flow Positive In Q4Benzinga Newsdesk - Jan 4, 2024, 7:12AM
Monday, November 13, 2023
Friday, November 10, 2023
Thursday, November 09, 2023
- Xeris Biopharma Says Confident To Achieve Cash Flow Breakeven In Q4Benzinga Newsdesk - Nov 9, 2023, 7:23AM
- Xeris Biopharma Tightens 2023 Revenue Guidance From $155M-$165M To $160M-$165MBenzinga Newsdesk - Nov 9, 2023, 7:22AM
- Xeris Biopharma Holdings Q3 EPS $(0.09) Vs. $(0.16) Last Year, Sales $48.32M Beat $41.08M EstimateBenzinga Newsdesk - Nov 9, 2023, 7:05AM
- Earnings Scheduled For November 9, 2023Benzinga Insights - Nov 9, 2023, 6:52AM
Monday, October 16, 2023
- Xeris Biopharma shares are trading higher after the company tightened FY23 revenue guidance and raised 2023 cash, cash equivalents and short-term investment guidance.Benzinga Newsdesk - Oct 16, 2023, 12:44PM
- Why Xeris Biopharma Shares Are Trading Higher TodayLekha Gupta - Oct 16, 2023, 9:25AM
- Xeris Biopharma's 2023 Cash Utilization Expected To Be $52M-$57MBenzinga Newsdesk - Oct 16, 2023, 7:07AM
- Xeris Biopharma Tightens FY23 Revenue Guidance From $145M-$165M To $155M-$165M Versus Consensus Of $158.2M; Raises 2023 Cash, Cash Equivalents, And Short-Term Investment Guidance From $55M-$65M to $65M-$70MBenzinga Newsdesk - Oct 16, 2023, 7:06AM
Wednesday, September 27, 2023
Monday, August 28, 2023
Thursday, August 10, 2023
Wednesday, August 09, 2023
Tuesday, August 08, 2023
- Xeris Biopharma Revises FY23 Revenue Outlook To $145M - $165M From $135M to $165M Vs. $149.35M Est.Benzinga Newsdesk - Aug 8, 2023, 7:05AM
- Xeris Biopharma Holdings Q2 EPS $(0.14) Misses $(0.13) Estimate, Sales $36.89M Beat $34.84M EstimateBenzinga Newsdesk - Aug 8, 2023, 7:02AM
- Earnings Scheduled For August 8, 2023Benzinga Insights - Aug 8, 2023, 4:48AM
Monday, August 07, 2023
Thursday, June 29, 2023
Wednesday, June 21, 2023
Wednesday, May 10, 2023
Tuesday, May 09, 2023
- Xeris Biopharma shares are trading higher after the company reported better-than-expected Q1 financial results.Benzinga Newsdesk - May 9, 2023, 12:14PM
- Xeris Biopharma Affirms FY23 GuidanceBenzinga Newsdesk - May 9, 2023, 7:10AM
- Xeris Biopharma Holdings Q1 EPS $(0.12) Beats $(0.17) Estimate, Sales $33.20M Beat $30.76M EstimateBenzinga Newsdesk - May 9, 2023, 7:09AM
- Earnings Scheduled For May 9, 2023Benzinga Insights - May 9, 2023, 6:03AM